07:00 , Jul 12, 2010 |  BioCentury  |  Strategy

Kamada's Liquidity Event

Although Kamada Ltd. 's Glassia is the fourth alpha-1 antitrypsin to reach the market in the U.S., the company expects its liquid formulation will allow it to carve out a niche in treating AAT deficiency....
08:00 , Jan 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Emphysema a1-Antitrypsin (SERPINA1; AAT; A1AT) A study in mice and in cell culture suggests that AAT gene therapy targeting alveolar macrophages could be useful...
02:06 , Jul 21, 2009 |  BC Extra  |  Company News

FDA panel wants clinical endpoints for AAT

FDA's Blood Products Advisory Committee voted 17-0 to recommend that change in lung density measured by high resolution computer tomography (HRCT) could be used as a primary endpoint in pivotal studies of inhaled alpha 1-antitrypsin...
07:00 , Apr 30, 2009 |  BC Innovations  |  Targets & Mechanisms

Moving upstream in thrombosis

Researchers at Tufts University School of Medicine think that inhibiting the MMP1 / PAR1 pathway could be a more effective way to prevent arterial thrombosis than using therapeutics that modulate thrombin itself, and it could...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Company News

ZephyrBiotech LLC supply/service news

ZephyrBiotech was formed to provide interim management professionals and project teams to virtual, seed and early stage biotech companies. ZephyrBiotech's two founding partners are Elise Brownell, formerly head of project management and senior director of...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

Alpha-1 antitrypsin: Phase IIb start

In 2Q09, Arriva will begin a double-blind, placebo-controlled, U.S. and European Phase llb trial of inhaled rAAT in about 50 patients. Arriva Pharmaceuticals Inc. , Alameda, Calif.   Product: Alpha-1 antitrypsin (AAT)   Business: Pulmonary...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Hyperion management update

Hyperion Therapeutics Inc. , South San Francisco, Calif.   Business: Metabolic, Neurology   Hired: Chris Rivera as president and CEO, formerly SVP of commercial operations at Tercica Inc. ; Sharron Gargosky as CSO and SVP...
07:00 , Sep 5, 2005 |  BC Week In Review  |  Company News

Arriva management update

Arriva Pharmaceuticals Inc. , Alameda, Calif.   Business: Pulmonary, Inflammation, Infectious   Hired: Gregory Ikonen as general counsel, formerly a partner at Heller Ehrman LLP  ...
07:00 , May 9, 2005 |  BC Week In Review  |  Company News

Arriva management update

Arriva Pharmaceuticals Inc. , Alameda, Calif.   Business: Pulmonary   Hired: Marvin Garovoy as CMO and VP of clinical development, formerly VP of clinical science at Xoma Ltd.  ...
07:00 , May 2, 2005 |  BioCentury  |  Finance

MPM's portfolio

MPM's portfolio Company Business Region Last MPM round (A) Date Raised MPM directors Acorda Neurology U.S. ND 5/9/03 $55.3 Michael Steinmetz Affymax Cancer; Hematology U.S. Series C 6/23/03 $40.0 Nicholas Galakatos Amphora Chemistry; Genomics U.S....